Cardiac Function and Ventricular Interactions in Persistent Pulmonary Hypertension of the Newborn.
Amish Jain, Afif F El-Khuffash, Claar H van Herpen...
https://pubmed.ncbi.nlm.nih.gov/33044416Actively Recruiting
Led by University of California, Davis · Updated on 2026-02-10
30
Participants Needed
1
Research Sites
N/A
Total Duration
U
University of California, Davis
Lead Sponsor
C
Children's Miracle Network
Collaborating Sponsor
Researchers are evaluating the effects of dopamine versus norepinephrine as first-line vasoactive treatments in term and late preterm newborns who have pulmonary hypertension related to low oxygen levels and systemic low blood pressure. This trial aims to compare how these drugs affect heart and lung function shortly after treatment begins. Pulmonary hypertension in newborns is a serious condition causing high resistance in lung vessels and poor oxygen delivery, often complicated by low blood pressure requiring medication support. Eligible infants receive either dopamine or norepinephrine through continuous intravenous infusions, adjusted to maintain blood pressure appropriate for their gestational age. Dopamine starts at 5 mcg/kg/min and can be increased to 20 mcg/kg/min, while norepinephrine starts at 0.02 mcg/kg/min and can be increased to 1 mcg/kg/min. This pilot study uses a time-based cluster randomization method, following standard care protocols in the neonatal intensive care unit, with additional echocardiographic monitoring for research purposes. Participants will undergo serial heart ultrasounds and oxygen level assessments within 30 hours after starting the assigned medication. Researchers will measure blood pressure ratios, heart output, oxygenation indices, and the need for other treatments like inhaled nitric oxide. Safety and heart function markers will also be monitored during this period. The study lasts until the primary evaluations are complete, with follow-up aligned to routine clinical care.
CONDITIONS
Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 hours after vasopressor initiation
Participants receive either dopamine or norepinephrine as first-line vasoactive therapy to manage systemic hypotension, with dosing adjusted to achieve appropriate blood pressure targets.
Continuous monitoring during infusion and 1 to 2 echocardiography assessments
Total: 1 location
1
UC Davis Children's Hospital
Sacramento, California, United States, 95817
Actively Recruiting
S
Solomon P Tatagiri, MBBS
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Amish Jain, Afif F El-Khuffash, Claar H van Herpen...
https://pubmed.ncbi.nlm.nih.gov/33044416Amy L Lesneski, Payam Vali, Morgan E Hardie...
https://pubmed.ncbi.nlm.nih.gov/34356574Heather M Siefkes, Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/33478959Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/22954275Pierre Tourneux, Thameur Rakza, Antoine Bouissou...
https://pubmed.ncbi.nlm.nih.gov/18534241Robin H Steinhorn
https://pubmed.ncbi.nlm.nih.gov/20216169Deepika Sankaran, Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/35963740Patrick J McNamara, Regan E Giesinger, Satyan Lakshminrusimha
https://pubmed.ncbi.nlm.nih.gov/35314154Jean-Michel Liet, Cécile Boscher, Christèle Gras-Leguen...
https://pubmed.ncbi.nlm.nih.gov/11953739P Y Cheung, K J Barrington
https://pubmed.ncbi.nlm.nih.gov/11353933